Equities analysts expect that Evolent Health Inc (NYSE:EVH) will report $188.85 million in sales for the current fiscal quarter, Zacks reports. Nine analysts have provided estimates for Evolent Health’s earnings. The highest sales estimate is $190.79 million and the lowest is $187.67 million. Evolent Health reported sales of $113.97 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 65.7%. The company is scheduled to announce its next earnings report after the market closes on Tuesday, February 26th.
On average, analysts expect that Evolent Health will report full-year sales of $627.33 million for the current financial year, with estimates ranging from $621.70 million to $629.89 million. For the next fiscal year, analysts expect that the firm will post sales of $849.75 million, with estimates ranging from $828.40 million to $875.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Evolent Health.
EVH has been the topic of several recent research reports. ValuEngine lowered shares of Evolent Health from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 1st. Piper Jaffray Companies reissued an “overweight” rating and set a $34.00 price target on shares of Evolent Health in a research report on Wednesday, November 7th. Wells Fargo & Co increased their price target on shares of Evolent Health from $26.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, November 7th. Zacks Investment Research raised shares of Evolent Health from a “hold” rating to a “buy” rating and set a $27.00 price target for the company in a research report on Tuesday, December 4th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $37.00 price target on shares of Evolent Health in a research report on Monday, December 31st. One investment analyst has rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $31.18.
Institutional investors and hedge funds have recently made changes to their positions in the business. Parkside Financial Bank & Trust boosted its position in Evolent Health by 57.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 3,628 shares of the technology company’s stock valued at $72,000 after buying an additional 1,327 shares during the period. We Are One Seven LLC purchased a new stake in shares of Evolent Health in the 4th quarter worth about $99,000. DekaBank Deutsche Girozentrale lifted its position in shares of Evolent Health by 235.4% in the 3rd quarter. DekaBank Deutsche Girozentrale now owns 6,205 shares of the technology company’s stock worth $156,000 after purchasing an additional 4,355 shares during the period. Public Employees Retirement Association of Colorado lifted its position in shares of Evolent Health by 106.3% in the 3rd quarter. Public Employees Retirement Association of Colorado now owns 6,904 shares of the technology company’s stock worth $196,000 after purchasing an additional 3,557 shares during the period. Finally, Jane Street Group LLC purchased a new stake in shares of Evolent Health in the 3rd quarter worth about $205,000.
EVH stock opened at $16.96 on Tuesday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 2.50 and a current ratio of 2.50. Evolent Health has a 52 week low of $13.25 and a 52 week high of $29.05. The firm has a market cap of $1.41 billion, a P/E ratio of -24.23 and a beta of 1.38.
Evolent Health Company Profile
Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.
Featured Article: Insider Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.